PMID- 36930100
OWN - NLM
STAT- MEDLINE
DCOM- 20230321
LR  - 20230916
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Print)
IS  - 0025-7974 (Linking)
VI  - 102
IP  - 11
DP  - 2023 Mar 17
TI  - Efficacy of Bushen Jiangu therapy in the treatment of glucocorticoid-induced 
      osteoporosis: A systematic review and meta-analysis of randomized controlled 
      trials.
PG  - e33278
LID - 10.1097/MD.0000000000033278 [doi]
LID - e33278
AB  - BACKGROUND: Glucocorticoid-induced osteoporosis (GIOP) is the most common 
      secondary osteoporosis. Bushen Jiangu (BSJG), a classic traditional Chinese 
      medicine (TCM) therapy, is widely used for treatment of GIOP. We conducted a 
      meta-analysis to evaluate the effectiveness and safety of BSJG therapy on the 
      treatment of GIOP. METHODS: We searched randomized controlled trials (RCTs) of 
      BSJG therapy for GIOP in 10 databases. Methodological quality assessment was 
      performed by using the Cochrane collaboration tool. RevMan v5.3 and Stata v14.0 
      software were used for performing data analysis. This study was conducted and 
      reported following the PRISMA checklist. RESULTS: Overall, 14 RCTs with 988 
      participants met the inclusion criteria. Pooled results indicated that BSJG 
      therapy contributed to a betterment in improving the clinical efficacy rate of 
      GIOP (risk ratio [RR] = 1.22, 95% confidence interval [CI]: 1.14, 1.30, P < 
      .00001). The pooled results also indicated that BSJG therapy increased lumbar 
      spine bone mineral density (LS-BMD) (weighted mean difference [WMD] = 0.21, 95% 
      CI: 0.08, 0.33, P = .001), total hip bone mineral density (TH-BMD) (WMD = 0.16, 
      95% CI: 0.09, 0.24, P < .0001), and femoral neck bone mineral density (FN-BMD) 
      (WMD = 0.07, 95% CI: 0.03, 0.10, P = .0001). Furthermore, our results indicated 
      that BSJG therapy improved visual analogue scale (VAS) score (WMD = -0.60, 95% 
      CI: -0.97, -0.23, P = .002), parathyroid hormone (PTH) (standardized mean 
      difference [SMD] = -0.93, 95% CI: -1.58, -0.27, P = .006), and N-terminal 
      propeptide of type I precollagen (PINP) (SMD = 0.69, 95% CI: 0.44, 0.95, P < 
      .00001). In terms of safety, there was no significant difference in the adverse 
      events (AEs) between the 2 groups (RR = 1.45, 95% CI: 0.63, 3.31, P = .38). 
      CONCLUSION: Our analysis indicates that BSJG therapy has a valid and safe effect 
      on the treatment of GIOP in the clinic. However, the results need to be confirmed 
      in more well-designed and large-scale RCTs.
CI  - Copyright (c) 2023 the Author(s). Published by Wolters Kluwer Health, Inc.
FAU - Yin, Xietian
AU  - Yin X
AUID- ORCID: 0000-0002-2088-5884
AD  - College of the First Clinical, Hubei University of Chinese Medicine, Wuhan, 
      China.
AD  - Department of Rheumatism Immunology, Hubei Provincial Hospital of TCM, Wuhan, 
      China.
FAU - Zhao, Shichao
AU  - Zhao S
AD  - Department of Geriatrics, Hubei Provincial Hospital of TCM, Wuhan, China.
FAU - Xiang, Nan
AU  - Xiang N
AD  - College of the First Clinical, Hubei University of Chinese Medicine, Wuhan, 
      China.
FAU - Chen, Jidong
AU  - Chen J
AD  - College of the First Clinical, Hubei University of Chinese Medicine, Wuhan, 
      China.
FAU - Xu, Jun
AU  - Xu J
AD  - College of the First Clinical, Hubei University of Chinese Medicine, Wuhan, 
      China.
FAU - Zhang, Yudan
AU  - Zhang Y
AD  - Hubei Provincial Key Laboratory of Occurrence and Intervention of Rheumatic 
      Diseases (Hubei Minzu University), Enshi, China.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Glucocorticoids)
RN  - 0 (Bone Density Conservation Agents)
SB  - IM
MH  - Humans
MH  - Glucocorticoids/adverse effects
MH  - Randomized Controlled Trials as Topic
MH  - *Osteoporosis/chemically induced/drug therapy
MH  - Bone Density
MH  - *Bone Density Conservation Agents/therapeutic use
PMC - PMC10019235
COIS- The authors have no conflicts of interest to disclose.
EDAT- 2023/03/18 06:00
MHDA- 2023/03/22 06:00
PMCR- 2023/03/17
CRDT- 2023/03/17 11:23
PHST- 2023/03/17 11:23 [entrez]
PHST- 2023/03/18 06:00 [pubmed]
PHST- 2023/03/22 06:00 [medline]
PHST- 2023/03/17 00:00 [pmc-release]
AID - 00005792-202303170-00037 [pii]
AID - 10.1097/MD.0000000000033278 [doi]
PST - ppublish
SO  - Medicine (Baltimore). 2023 Mar 17;102(11):e33278. doi: 
      10.1097/MD.0000000000033278.